Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lexeo Therapeutics
Biotech
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Ex-CRISPR Tx CMO lands at Takeda. Lexeo adds Pfizer rare disease leader as development chief. Merck & Co. leader to join Cartography.
Max Bayer
,
Gabrielle Masson
Feb 9, 2024 9:30am
Lexeo drops share price at last minute to raise $100M IPO
Nov 3, 2023 8:19am
Two biotechs go public while Apnimed bides its time
Oct 2, 2023 11:02am
Fierce Biotech's 2022 Fierce 15
Sep 12, 2022 3:00am
Lexeo keeps foot on the gas pedal with $100M financing
Sep 9, 2021 6:00am
Lexeo bolsters rare heart disease pipeline with Stelios buy
Jul 21, 2021 8:30am